Northwest Biotherapeutics Inc financial data

Symbol
NWBO on OTC
Industry
Pharmaceutical Preparations
Location
4800 Montgomery Lane, Suite 800, Bethesda, MD
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 7.78 % -47.9%
Debt-to-equity -113 % -4.84%
Return On Equity 103 % +4.32%
Return On Assets -297 % -43.1%
Operating Margin -4.36K % -38.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.39B shares +16.3%
Common Stock, Shares, Outstanding 1.33B shares +13%
Entity Public Float 511M USD -17.2%
Common Stock, Value, Issued 1.33M USD +13%
Weighted Average Number of Shares Outstanding, Basic 1.24M shares +11%
Weighted Average Number of Shares Outstanding, Diluted 1.24M shares +11%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.34M USD -38.1%
Revenue from Contract with Customer, Excluding Assessed Tax 357K USD -12.1%
Research and Development Expense 34.9M USD +25.8%
General and Administrative Expense 33M USD +11.1%
Operating Income (Loss) -66.5M USD -19.8%
Net Income (Loss) Attributable to Parent -83.8M USD -33.8%
Earnings Per Share, Basic -0.07 USD/shares -16.7%
Earnings Per Share, Diluted -0.07 USD/shares -16.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.18M USD +2.31%
Assets, Current 4.06M USD -1.53%
Property, Plant and Equipment, Net 16.2M USD -6.26%
Operating Lease, Right-of-Use Asset 4.19M USD +0.1%
Goodwill 626K USD 0%
Other Assets, Noncurrent 365K USD +1.11%
Assets 26.7M USD -4.08%
Liabilities, Current 68.3M USD +51%
Operating Lease, Liability, Noncurrent 4.44M USD -0.36%
Liabilities 106M USD +41.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3.04M USD +98.1%
Retained Earnings (Accumulated Deficit) -1.44B USD -6.16%
Stockholders' Equity Attributable to Parent -94.5M USD -43.7%
Liabilities and Equity 26.7M USD -4.08%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.4M USD -10.4%
Net Cash Provided by (Used in) Financing Activities 12.1M USD -3.95%
Net Cash Provided by (Used in) Investing Activities -239K USD +82.1%
Common Stock, Shares Authorized 1.7B shares 0%
Common Stock, Shares, Issued 1.33B shares +13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 352K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.18M USD +2.31%
Deferred Tax Assets, Valuation Allowance 281M USD +7.56%
Deferred Tax Assets, Gross 281M USD +7.56%
Operating Lease, Liability 4.76M USD -0.08%
Depreciation 400K USD +33.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -83.7M USD -26.8%
Lessee, Operating Lease, Liability, to be Paid 9.53M USD -5.78%
Operating Lease, Liability, Current 326K USD +3.82%
Lessee, Operating Lease, Liability, to be Paid, Year Two 842K USD +27.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 885K USD +2.08%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.77M USD -10.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 652K USD -1.51%
Deferred Tax Assets, Operating Loss Carryforwards 222M USD +5.1%
Preferred Stock, Shares Authorized 100M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 652K USD -1.51%
Operating Lease, Payments 241K USD +7.11%
Share-based Payment Arrangement, Expense 3.46M USD -21.6%
Interest Expense 5.73M USD +10.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%